ICH Project ICH Q11 guideline information session ICH Q11: Development and Manufacturing of Active Pharmaceutical Ingredients (Chemicals and Biotechnology-applied Drugs/Biologically-derived Pharmaceuticals)

Jul 13, 2011

ICH is considering the development of a high-level guideline based on a common concept for the development and manufacturing of active pharmaceutical ingredients (API) for both chemicals and biotechnology-derived/biologically-derived pharmaceuticals (Q11). Progress has been slower than originally planned due to the complexity and uniqueness of the subject area (combining both chemicals and biotechnology-derived pharmaceuticals under a common concept), but we have now reached Step 2. This time, a briefing on the newly developed Q11 Step 2 Guideline, including its background, was held. Approximately 400 people from the pharmaceutical industry and other related parties attended the meeting, where a lively question-and-answer session was held.

The following is a list of the presentation materials used at the briefing.
Unauthorized copying or reproduction of any of the materials is strictly prohibited.

Date, time and place

Date and Time Location
Friday, August 5, 2011, 10:00-16:55 Tower Hall Funabori Main Hall
4-1-1 Funabori, Edogawa-ku, Tokyo

Information and Program

Information (200KB)

Briefing Materials

Horizontal scrolling is available

Briefing Materials Presentation materials Speakers (titles omitted)

Session A: Objectives of the ICH Q11 Guideline and Outcomes of the 2010 MHLW Research Group Meeting (1,515KB)

   

Haruhiro Okuda
Department of Pharmaceuticals, National Institute of Health Sciences

Session B: Overview of ICH Q11 Guideline

 

Session 1:History of the development of manufacturing processes(802KB)

 

Example 1

Kazunori Takagi
New Drug Evaluation Department 3, Pharmaceuticals and Medical Devices Agency

 

Example 2

Koji Takagi
ICH Project Q11 Topic Leader, Japan Pharmaceutical Manufacturers Association

 

Presentation 2: Selection of starting materials and biogenic raw materials (940KB)

 

Example 4

Kiyotoshi Matsumura
ICH Project Q11 Expert, Japan Pharmaceutical Manufacturers Association

 

Research Group Exemplification

Haruhiro Okuda
Department of Pharmaceuticals, National Institute of Health Sciences

 

Exemplification 3: Management Strategies

Tsuyoshi Ando
Translational Research Center, The University of Tokyo Hospital

 

Presentation 4: Process validation/process evaluation (example 3) (980KB)

 

Presentation 5: Submission of manufacturing process development information and related information in Common Technical Document (CTD) format and life cycle management (Example 5) (775KB)

Tomonori Nakagawa
ICH Project Q11 Expert, Japan Pharmaceutical Manufacturers Association

For inquiries, please contact

ICH Secretariat of the Pharmaceutical Manufacturers' Association of Japan

Phone
03-3241-0326

The End

Share this page

TOP